<div id="readability-page-1"><p>Covea Finance decreased its position in shares of  Zoetis Inc. (NYSE:ZTS - Free Report) by 7.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor  owned 264,497 shares of the company's stock after selling 22,300 shares during the quarter. Zoetis makes up  approximately  1.3% of Covea Finance's holdings, making the stock its 22nd largest holding. Covea Finance owned about 0.06% of Zoetis worth $38,701,000 as of its most recent filing with the SEC.</p><ul><li>Which Pet Stock Should Get Your Tail Wagging in 2024?</li></ul><p>Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Nova Wealth Management Inc. bought a new position in  Zoetis in the first quarter valued at about $25,000.  1248 Management LLC bought a new stake in  Zoetis during the 1st quarter worth about $27,000.  Saudi Central Bank acquired a new position in  Zoetis during the 1st quarter valued at about $29,000.  REAP Financial Group LLC boosted its stake in shares of  Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company's stock valued at $31,000 after purchasing an additional 131 shares during the last quarter.  Finally, NewSquare Capital LLC grew its position in shares of  Zoetis by 69.1% during the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company's stock worth $32,000 after buying an additional 85 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several equities analysts recently weighed in on the stock. Argus  restated a &#34;buy&#34; rating and issued a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. JPMorgan Chase &amp; Co. reduced their price target on Zoetis from $230.00 to $200.00 and set an &#34;overweight&#34; rating on the stock in a research report on Wednesday, November 5th. Morgan Stanley  set a $160.00 price objective on Zoetis in a research note on Thursday, December 18th. KeyCorp began coverage on Zoetis in a research note on Thursday, November 20th. They issued a &#34;sector weight&#34; rating on the stock. Finally, Stifel Nicolaus reduced their target price on Zoetis from $140.00 to $130.00 and set a &#34;hold&#34; rating on the stock in a report on Tuesday, November 18th. Six research analysts have rated the stock with a Buy rating, seven have issued  a Hold rating and one  has given a Sell rating to the stock. According to MarketBeat.com, Zoetis presently has an average rating of &#34;Hold&#34; and an average price target of $160.18.</p><ul><li>MarketBeat Week in Review – 07/31 - 08/04</li></ul><p><b>Check Out Our Latest Report on ZTS</b></p><h2>Zoetis Price Performance</h2><p>Shares of ZTS opened at $125.50 on Friday. The stock has a 50 day simple moving average of $127.41 and a 200 day simple moving average of $143.41. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.40. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The firm has a market capitalization of $55.31 billion, a PE ratio of 21.13, a P/E/G ratio of 2.73 and a beta of 0.97. </p><ul><li>Rising Dividend Make Zoetis a Doggone Winner</li></ul><p>Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business's revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS.  Sell-side analysts predict that  Zoetis Inc. will post 6.07 EPS for the current fiscal year. </p><h2>Zoetis Increases Dividend</h2><p>The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. This is a boost from Zoetis's previous quarterly dividend of $0.50. Zoetis's dividend payout ratio (DPR) is currently 33.67%. </p><h2>Zoetis Profile</h2> (Free Report)<p>Zoetis Inc <span>NYSE: ZTS<span></span></span> is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.  </p><p>Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.</p><h2>Read More</h2><ul><li>Five stocks we like better than Zoetis</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li><li>Washington prepares for war</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>The McDonald's Secret</li><li>33,000% boom from weird new “AI Fuel?”</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Zoetis Right Now?</h2><p>Before you consider Zoetis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.</p><p>While Zoetis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Covea Finance reduced its stake in Zoetis Inc. by 7.8% in the third quarter, selling 22,300 shares. Zoetis now represents 1.3% of Covea's holdings. The stock is held by 92.80% institutional investors. Analysts have mixed ratings on Zoetis, with a current average rating of 'Hold' and a price target of $160.18. Zoetis reported strong quarterly earnings and increased its dividend, with a new annual yield of 1.7%.</p>

Covea Finance Sells 22,300 Shares of Zoetis Inc. $ZTS